2.
影响安罗替尼联合替吉奥治疗复发转移性食管鳞癌PFS的单因素分析
Univariate analysis of progression-free survival in the 26 patients after treatment with anlotinib plus S-1
| Characteristics | No. of patients | Median PFS (95%CI) | P |
| Gender | 0.621 | ||
| Male | 23 | 4.5 (2.4-6.7) | |
| Female | 3 | 7.6(0.0-16.6) | |
| Age | 0.296 | ||
| ≤65 years | 10 | 4.6 (4.2-5.0) | |
| > 65 years | 16 | 3.2(1.1-5.4) | |
| Radical Surgery | 0.834 | ||
| Yes | 13 | 3.8(0.7-6.8) | |
| No | 13 | 4.8(2.8-6.7) | |
| Radiotherapy | 0.226 | ||
| Yes | 4 | 3.1 (1.2-4.9) | |
| No | 22 | 4.6 (2.7-6.5) | |
| ECOG PS score | 0.330 | ||
| 0-1 | 17 | 4.6 (2.5-6.7) | |
| 2 | 9 | 3.8(0.0-9.4) | |
| Differentiation grade | 0.007 | ||
| Low | 14 | 1.9 (0.5-3.4) | |
| Medium-high | 12 | 6.1 (4.4-7.8) | |
| Distal metastasis | 0.087 | ||
| Yes | 24 | 4.6 (3.4-5.8) | |
| No | 2 | 1.9(-) | |
| Liver metastasis | 0.318 | ||
| Yes | 9 | 4.5 (2.3-6.8) | |
| No | 17 | 4.7 (2.4-7.0) |